J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study

J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study kdunleavy Wed, 10/02/2024 - 14:19